UCB PHARMA SA
🇧🇪Belgium
- Country
- 🇧🇪Belgium
- Ownership
- Public, Subsidiary
- Established
- 1928-01-01
- Employees
- 9K
- Market Cap
- $34.9B
Clinical Study in Healthy Volunteers to Investigate the Neurocognitive Effects of a New Antiepileptic Drug: Brivaracetam
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-08-18
- Last Posted Date
- 2012-05-28
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 20
- Registration Number
- NCT00736931
CDP323 Biomarker Study
- First Posted Date
- 2008-08-01
- Last Posted Date
- 2011-09-12
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 71
- Registration Number
- NCT00726648
Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-07-17
- Last Posted Date
- 2018-08-01
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 1648
- Registration Number
- NCT00717236
A Double-blind, Randomized Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (≥ 16 to 75 Years Old) With Partial Onset Seizures
- First Posted Date
- 2008-06-17
- Last Posted Date
- 2018-07-11
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 62
- Registration Number
- NCT00699283
A Double-blind, Randomized Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (≥ 16 to 75 Years Old) With Partial Onset Seizures
- First Posted Date
- 2008-06-17
- Last Posted Date
- 2018-07-11
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 88
- Registration Number
- NCT00698581
Rheumatoid Arthritis (RA) Moderate to Low Disease Activity Study
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-05-07
- Last Posted Date
- 2012-01-18
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 194
- Registration Number
- NCT00674362
Open-label Study of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus Patients With Active Disease
- First Posted Date
- 2008-04-17
- Last Posted Date
- 2012-07-12
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 210
- Registration Number
- NCT00660881
A Study Evaluating the Efficacy and Impact on Health-related Quality of Life of Levocetirizine in Adults With Seasonal Allergic Rhinitis
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-04-04
- Last Posted Date
- 2011-08-31
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 580
- Registration Number
- NCT00653224
Pharmacovigilance Study of Keppra. SPAIN - SKATE : Safety of Keppra as Adjunctive Therapy in Epilepsy
Phase 4
Completed
- Conditions
- First Posted Date
- 2008-03-26
- Last Posted Date
- 2013-11-15
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 342
- Registration Number
- NCT00643500
Efficacy and Safety of Cetirizine Tablets Versus Ketotifen Dry Syrup in Children With Perennial Allergic Rhinitis
Phase 3
Completed
- Conditions
- First Posted Date
- 2008-03-20
- Last Posted Date
- 2009-09-04
- Lead Sponsor
- UCB Pharma
- Target Recruit Count
- 149
- Registration Number
- NCT00639587
© Copyright 2024. All Rights Reserved by MedPath